The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology and as analytical and therapeutic agents. There was agreement that ncRNA expression profiling data requires careful evaluation to determine the utility of specific ncRNAs as biomarkers. To advance the use of ncRNA in regulatory toxicology, the following research priorities were identified: (1) Conduct comprehensive literature reviews to identify possibly suitable ncRNAs and areas of toxicology where ncRNA expression profiling could address prevailing scientific deficiencies. (2) Develop consensus on how to conduct ncRNA expression profiling in a toxicological context. (3) Conduct experimental projects, including, e.g., rat (90-day) oral toxicity studies, to evaluate the toxicological relevance of the expression profiles of selected ncRNAs. Thereby, physiological ncRNA expression profiles should be established, including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for cell homeostasis or pathogenesis, molecular events should be dose-dependently linked with substanceinduced apical effects. Applying a holistic approach, knowledge on ncRNAs, 'omics and epigenetics * Corresponding author. ECETOC
a b s t r a c t
The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology and as analytical and therapeutic agents. There was agreement that ncRNA expression profiling data requires careful evaluation to determine the utility of specific ncRNAs as biomarkers. To advance the use of ncRNA in regulatory toxicology, the following research priorities were identified: (1) Conduct comprehensive literature reviews to identify possibly suitable ncRNAs and areas of toxicology where ncRNA expression profiling could address prevailing scientific deficiencies. (2) Develop consensus on how to conduct ncRNA expression profiling in a toxicological context. (3) Conduct experimental projects, including, e.g., rat (90-day) oral toxicity studies, to evaluate the toxicological relevance of the expression profiles of selected ncRNAs. Thereby, physiological ncRNA expression profiles should be established, including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for cell homeostasis or pathogenesis, molecular events should be dose-dependently linked with substanceinduced apical effects. Applying a holistic approach, knowledge on ncRNAs, 'omics and epigenetics 1. Introduction
Background
Non-(protein-)coding RNAs (ncRNAs) are broadly classified according to their length as long noncoding RNAs (lncRNAs; >150e200 nucleotides (nt)) and short ncRNAs (<150e200 nt) (Wright and Bruford, 2011) . Between 4 and 10% of lncRNAs are further processed to shorter RNAs (Kapranov et al., 2007; Derrien et al., 2012) . Major classes of short ncRNAs include:
1. Endogenous microRNAs (miRNAs; single-stranded, approx.
19e25 nt). MiRNAs are first produced as double-stranded RNA molecules. In this duplex form, they can also be used as therapeutic agents. Mature miRNAs are associated with the RNAinduced silencing complex, where they predominantly repress gene expression by inducing messenger RNA (mRNA) degradation or inhibiting mRNA translation (Kim, 2005; Winter et al., 2009 ); 2. Endogenous piwi-interacting RNA (piRNA; single-stranded, approx. 24e31 nt). PiRNAs are believed to be involved in germ cell formation by post-transcriptional silencing of retrotransposons and mRNAs in reproductive organs (Watanabe et al., 2006 (Watanabe et al., , 2011 Kuramochi-Miyagawa et al., 2008; Gou et al., 2014; Williams et al., 2015) ; 3. Endogenous or synthetically produced short interfering RNAs (siRNAs; double-stranded, 20e24 nt). Endogenous siRNAs are also involved in the post-transcriptional silencing of retrotransposons and mRNAs (Watanabe et al., 2006 . Synthetically produced siRNAs are used as research tools in test animals (Arrigo and Pulliero, 2015; Wright and Bruford, 2011) or as therapeutic agents, with several candidates currently being tested in clinical studies.
Since knowledge on the existence and functionalities of different forms of ncRNAs is evolving rapidly, this classification of different forms of ncRNA is most likely not definite. Further classes of short ncRNAs are known and continue to be discovered, e.g. small nuclear RNA, small nucleolar RNA, vault RNA, or Y RNA (Stadler et al., 2009; Martens-Uzunova et al., 2013; Kowalski and Krude, 2015) .
Generally, endogenous ncRNAs have been found to be involved in post-transcriptional gene silencing, epigenetic regulation and the mediation of physical and chemical environmental signals. Although knowledge on how substances can influence the functionality of ncRNAs is growing, the potential role of ncRNAs in regulatory toxicology and the risk assessment (RA) of substances remains to be evaluated.
(Throughout this report, the term 'substance' is used as defined in Regulation (EC) No 1907/2006 on the Registration, Authorisation, Evaluation and Restriction of Substances (REACH), i.e. a chemical element and its compounds in the natural state or obtained by any manufacturing process, including, as applicable, necessary stabilizing additives and impurities deriving from the given production process.)
Workshop structure and aims
To assess recent progress made on the basic research and use of ncRNAs as biomarkers in regulatory toxicology and as analytical and therapeutic agents, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) organised the workshop ncRNAs and risk assessment science. Twenty-two experts representing academia, authorities, industry, and independent consultants attended this workshop that took place on 3 and 4 March 2016 in M alaga, Spain (cf. Appendix for list of participants). As Alan Poole, Secretary General of ECETOC, Belgium, outlined in the opening, the workshop aimed at reaching a common understanding on the state-of-the-art research on ncRNAs, on the implications of ncRNA expression profile changes for the evolvement of apical effects (i.e. the observable outcomes of substance exposure to test animals (OECD, 2012) ), and the current and potential future role of ncRNAs in regulatory toxicology and RA. The first day of the workshop comprised a series of presentations, a panel and extensive plenary discussions. These sessions focused on understanding the physiology and mechanisms of action of ncRNAs, their functional relevance and possible role in human pathology, and the potential use of ncRNAs in toxicology and the RA of substances. On the second day, three breakout groups were formed. In a first session, the breakout groups further discussed means to analyse and interpret data from ncRNA expression profiling for regulatory toxicology and RA and addressed the question to what extent current regulatory toxicology would benefit from the evolving knowledge on ncRNA. In a second session, research priorities were identified to advance the use of ncRNAs as biomarkers in regulatory toxicology and RA. In the long term, all such research should serve the 3Rs principle to replace, reduce and refine animal testing (Russell and Burch, 1959) that has been implemented in Directive 2010/63/EU on the protection of animal used for scientific purposes. Furthermore, use of ncRNAs in regulatory toxicology might serve to improve cost efficiency and the timely access to new product developments.
Presentation summaries
2.1. What are ncRNAs and, specifically, miRNAs? Tim Gant, Head of Toxicology, Centre for Radiation, Chemical and Environmental Hazards, Public Health England (PHE), UK
In searching for ncRNAs as useful biomarkers for regulatory toxicology, the class of miRNAs may merit special consideration as their functions in controlling gene expression in a wide variety of cellular processes (including proliferation, differentiation and development) as well as their involvement in toxicological and pathological processes is currently best understood. Further, some miRNAs exhibit organ-specific expression, and they can be detected in the blood plasma. As such, they can act as distant biomarkers of adverse events. Nevertheless, the potential utility of other forms of ncRNAs should also be investigated, since they will most likely assume an equal status as their roles in physiology and disease are better understood.
MiRNAs regulate gene expression at the post-transcriptional level, i.e. after the given segment of the DNA has been copied into mRNA. Predominantly, miRNAs degrade mRNAs or they inhibit the translation of specific mRNA by binding to their 3'-untranslated regions (3 0 -UTR), i.e. regions that can influence the translation efficiency of the mRNAs. Further, miRNAs appear to play a role in the transgenerational transmission of altered phenotypes through the male germ line. Compared with mRNAs, only a small number of miRNAs have been identified, i.e. 4552 unique human miRNAs (at the time of writing the workshop report) as compared to 30,000 known human mRNAs. However, one miRNA can regulate the expression of many mRNAs (by partial complementary base pairing). Hence, even though miRNAs are smaller in number, their effects on the phenotype of cells can be substantial (Hannon and Rossi, 2004) . On the other hand, different miRNAs can regulate the same target gene. Therefore, it is necessary to carefully evaluate the specific contribution of a given miRNA. By controlling mRNA translation, miRNAs elicit effects on the cellular protein levels. Generally, the more miRNA is present in a cell, the less protein will be translated (Selbach et al., 2008) . MiRNAs can be tissue-specific, e.g. miR-124 in the brain, miR133a in the heart, or miR-122 in the liver, the latter being well explored in regard to drug overdose-induced hepatotoxicity (Laterza et al., 2009 ). Tissue-specific miRNAs can be relevant biomarkers for regulatory toxicology, even more so since they are stable and can be found in all body fluids. Finally, miRNA can play a role in the evolvement of chromosome aberrations (Calin and Croce, 2006) .
In the human genome, the majority of miRNAs is located in between genes (i.e. they are intergenic), where miRNAs are organised into cistronic and polycistronic regions, i.e. regions that express one or more miRNAs, respectively (He et al., 2005) . Nevertheless, miRNAs are also found in the introns of genes, in which case they are controlled by a mRNA promoter and enhancer region. Such miRNAs often act as feedback loops to the genes in which they are contained. Finally, the smallest group of miRNAs are exonic (Gant et al., 2015) . During embryonic development, miRNAs can be involved in the very early stages of gene transcription that begins in zygotes during the eight-cell stage. It is hypothesized that, if such gene transcription processes are disturbed, e.g. by environmental or epigenetic factors, the phenotype of the resulting embryo can potentially be affected (Trerotola et al., 2015) .
Mechanisms of action of ncRNAs and functional relevance
Gunter Meister, Biochemistry Centre Regensburg, Regensburg University, Germany
Small ncRNAs are found in all higher eukaryotes. They play key regulatory roles in cellular processes that are as diverse as embryonic development, stress response and transposon silencing. All small ncRNA species are generated from longer precursor molecules and are finally incorporated into effector protein complexes. Of the small ncRNAs, recent research has focused on miRNAs that guide post-transcriptional, temporary gene silencing. This is mediated by members of the so-called argonaute (AGO) protein family that bind to the miRNAs (Huntzinger and Izaurralde, 2011; Meister, 2013; Schraivogel and Meister, 2014; Dueck and Meister, 2014; Jonas and Izaurralde, 2015) .
Second, lncRNAs are being extensively studied. In mammals, lncRNAs are found in the nucleus and in the cytoplasm. In the nucleus, they mainly associate with chromatin and regulate the expression of specific genes. In the cytoplasm, they can bind to mRNAs thereby also influencing post-transcriptional gene expression. LncRNAs can function as guides (enhancers of proper localization of protein complexes), sponges (by binding to complementary RNAs which inhibits their functionality), scaffolds (adaptors to bring two or more proteins into discrete complexes) or even nucleators for higher order chromatin structures (Ebert and Sharp, 2010; Salmena et al., 2011; Rinn and Chang, 2012) . Similar to small ncRNAs, lncRNA expression is frequently altered in human diseases.
Recently, circular RNAs have been characterized (Hentze and Preiss, 2013) . Circular RNAs can be abundant under specific conditions or in specific tissues (e.g. the brain); they are generated by alternative splicing, and they can act as sponges for RNAs and proteins. Apparently, some circular RNAs even have coding potential and can contribute to the diversification of gene products.
Finally, epitranscriptome, i.e. sugar or base modifications that are introduced into mRNAs (i.e. the transcriptome) after synthesis, constitute procedures that, similar to epigenetics, exist 'on top' of the synthesis of coding and non-coding transcripts. For many years, it has been known that ribosomal and transfer RNAs can be modified at particular bases. Recently, it was found that mRNAs can also be modified and that this can influence gene expression. RNAbinding proteins can associate with transcripts, thereby changing their function independently of their sequence. Further, RNAs were found to cross-talk by hybridisation, i.e. pairing to complementary RNA (Lin and Gregory, 2014) . All of these factors should be taken into account when analysing gene expression. Most likely, to date, only the 'tip of the iceberg' has been uncovered, and many more such modifications with important biological functions remain to be detected. MiRNAs can play regulatory roles by pairing to the mRNAs of protein-coding genes to direct their post-transcriptional repression (Bartel, 2009) . According to the current view, each miRNA regulates hundreds of genes (Lam et al., 2015) . Computational tools aim at identifying miRNA targets, looking for seed-matches (i.e. complementary sequences) in the 3 0 UTRs of miRNAs and mRNAs (Bartel, 2009) . Usually, this is performed by selecting evolutionarily conserved miRNA binding sites. However, frequently, such predictions are biologically irrelevant, since short matches are very frequent. Sixty per cent of human coding genes seem to be targeted (Friedman et al., 2009) , and miRNAs are implicated in every physiological process in animals. Nevertheless, miRNA-mediated gene repression is usually very modest, i.e. less than two-fold, which is lower than well-tolerated fluctuations in gene expression. Focusing on miR-223-guided gene repression, Baek et al. (2008) measured miRNA-guided repression in vivo. Work conducted in the presenter's laboratory shows that inter-individual variability in wildtype mice is larger than miR-223-guided repression for 150 out of 192 predicted targets. Hence, most predicted targets appear functionally insensitive to the miRNAs. Moreover, many conserved miRNA binding sites appear to be conserved in a miRNAindependent fashion. It is unclear, why miRNA binding sites have been conserved since they do not appear to be functional. Sequence elements can be conserved for other reasons, while being fortuitously complementary to miRNAs. Accordingly, comparative genomics can yield a high proportion of false positive results.
In revisiting the definition of a 'miRNA target' it is concluded that not every measurable change in gene expression translates into a macroscopic, evolutionarily selectable phenotype. The role of miRNAs in normal and pathological conditions might have been over-estimated, and the very notion of 'gene regulation' should be reconsidered taking into account the robustness of cellular homeostasis to external insults. It appears difficult to reconcile such observations with the extreme sensitivity required for genetic fine-tuning. Most likely, the 'butterfly effect' (indicating that a small dose can trigger a substantial consequence, i.e. phenotypic alteration) has been counter-selected for.
2.4. Cellular adaptation: relevance for risk assessment and physiological interpretation Emma Marczylo, PHE, UK The vast majority of the mammalian genome is composed of socalled noncoding DNA, whereas only approx. 1e2% of the mammalian genome code for proteins. The majority of noncoding DNA is transcribed into ncRNAs, which play major roles in regulating gene expression. Whilst lncRNAs do this in a variety of ways, including chromosome remodelling and transcriptional or posttranscriptional regulation, short ncRNAs predominantly regulate gene expression at the post-transcriptional level. NcRNAs interact with epigenetic mechanisms to form a robust regulatory epigenetic network . Many ncRNAs, particularly miRNAs, have been shown to be involved in both toxicity and disease. Specifically, ncRNA play a central role during cellular adaptation in response to changes in the environment. Following exposure to an environmental stressor, cellular processes are activated in an attempt to regain homeostasis. These processes can be transient, returning to the original state once the insult is removed, or they can become established as the 'new homeostasis'. Such adaptations can be positive, providing protection against further stress (Wheeler and Wong, 2007; Jain et al., 2014) ; or they can be negative, resulting in an increased susceptibility to further stress (Greathouse et al., 2012; Wong et al., 2015) . If cells are unable to adapt to an environmental stressor, adverse effects can evolve that can either be reversible (leading back to homeostasis) or irreversible which ultimately results in cell death. For RA, it is important to distinguish between cellular adaptation and adverse effects.
In determining cellular 'normality' with the aim of making use of ncRNAs for RA, it is important to understand and characterise the variability in ncRNAs (both within individuals (tissue specificity) and between different individuals and different species) that are present in the same steady state (normal environment). For instance, more than 500 different miRNAs were present in the plasma of 18 disease-free human volunteers. Of these, approx. 50 miRNAs were present in all samples. Further, 10 of the most highly expressed miRNAs accounted for 90% of the total miRNA expression, and 5 of these were blood cell-associated. Finally, 10 of the most stably expressed miRNAs included 5 of the most highly expressed (Tonge and Gant, 2016) . Variability in ncRNA expression should also be understood in response to changes in the normal environment that do not exert adverse effects both within individuals and between individuals. This will enable identification of genetic susceptibilities, normal ranges of ncRNA expression, and adaptations with increased susceptibilities to further stresses/exposures.
In determining the relevance of miRNA-initiated cellular adaptations to environmental stressors, it is important to distinguish whether the change in ncRNA expression is the cause or the consequence of an apical effect. Yet, whilst a robust, dosedependent relationship between specific ncRNA(s) and environmental stressor(s) or subsequent effect(s) is vital for RA, establishing causality is not necessarily essential. NcRNAs that do not in themselves directly induce adverse effect(s), but instead act as markers of exposure and/or predictors of future toxicity, can also be useful in regulation . Increasingly, the potential use of miRNAs as biomarkers is being investigated since they are secreted in multiple body fluids (including blood, semen, saliva), and they are stable (secreted within exosomes), accessible, and easily measured (Gant et al., 2015) . Spermatozoal miRNAs are of particular interest for regulatory purposes since they can be altered by environmental exposures, transmitted across generations, involved in the physiological or pathophysiological development of subsequent progeny and are easily collected and analysed (Liu et al., 2012; Marczylo et al., 2012; Rodgers et al., 2013 Rodgers et al., , 2015 Gapp et al., 2014; Stowe et al., 2014) . To be used as biomarkers, ncRNAs should further be sensitive, specific, and linearly related to exposure and effect.
With regard to the physiological interpretation (i.e. phenotypic anchoring) of alterations in ncRNA expression, these molecules pose unique challenges since they act at multiple levels forming part of an interactive network. For example, miRNAs have multiple mRNA targets, just as potential mRNA targets are targeted by multiple miRNAs. Consequently, the interpretation of observations can be challenging. To facilitate phenotypic anchoring, ncRNA expression profiles can be correlated with other profiles and phenotypic endpoints (Akinjo et al., 2016) . In this respect, 'omics technologies allow simultaneous profiling of multiple variables using a systems biology approach.
In conclusion, ncRNAs are important regulators of gene expression and represent novel mechanisms and markers of toxicity that might be useful for regulatory purposes. To explore such use, a greater mechanistic understanding should be obtained, e.g., by performing additional analyses on surplus biological samples from existing regulatory studies, thereby avoiding the use of extra animals. It might also be considered to adapt existing testing guidelines to incorporate ncRNA analyses, as appropriate, to begin collecting data on ncRNA in a regulatory context. In cross-kingdom RNA communication, the nematode Caenorhabditis elegans is the known champion, using ingested environmental RNA as a type of immune system (Jose, 2015) . Such crosskingdom communication has also been described or proposed in various host-pathogen interactions, e.g., in the relationship of retroviruses with their hosts (Klase et al., 2007; Wagschal et al., 2012; van Dongen et al., 2016) . Applied to mammals, the so-called 'dietary RNA hypothesis' suggests that intact RNAs present in the food might enter the ingesting organism and exert gene expressional functions in its cells (Witwer and Hirschi, 2014) . Studies of mammalian uptake have focused mostly on miRNAs, or 'xenomiRs' to denote their foreign origin. However, in the meantime, enthusiasm about the absorption and function of xenomiRs has been diminished by negative findings and evidence of contamination and experimental design flaws that account for apparently positive results (Mlotshwa et al., 2015) . Nevertheless, despite scant and suspect evidence for the hypothesis, interest is likely to continue into the foreseeable future. Focusing on mammals exposed to plants and milk (Dickinson et al., 2013; Snow et al., 2013; Witwer et al., 2013; Baier et al., 2014; Tosar et al., 2015) , experimental results and current understanding of RNA stability, transport, and function do not appear to be consistent with proposed forms of cross-kingdom communication. In many cases, presumably positive ncRNA findings were shown to result from, e.g., sample contaminations or artefacts caused by technical limitations of the applied technologies (Witwer, 2015 Considering that mammalian cells are capable of producing a plethora of ncRNAs, the question arises to which extent non-coding transcription is functionally important. Are changes in ncRNA expression causal for diseased or adverse states or a consequence thereof? Even if the latter is the case, ncRNAs might still form a valuable pool for biomarkers of adversity or disease. However, if ncRNAs play in part causal roles, do we need to consider ncRNAs in mode-of-action (MoA) frameworks or adverse outcome pathways (AOPs; Ankley et al., 2010) ? If so, is it already possible to define MoAs or AOPs where ncRNAs participate in key events?
The example of interleukin 6 (IL-6) and signal transducer and activator of transcription 3 (STAT3)-controlled ncRNAs served to further elucidate these questions. Specific multiple myeloma (B cell malignancy) cells depend strictly on IL-6 and become apoptotic when IL-6 is not present. However, this cellular phenotype cannot be explained by an IL-6-enabled differential expression of proteincoding genes (Brocke-Heidrich et al., 2004) . Instead, the miRNA miR-21 appears responsible for the anti-apoptotic effect of IL-6 and indeed shows strong differential expression in B cell malignancy cells (L€ offler et al., 2007) . Further, miR-21 has been observed to target the tumour suppressor genes ANP32A, PDCD4 and SMARCA4 (Schramedei et al., 2011) . IL-6 and STAT3 have been observed to control a plethora of lncRNAs and to regulate a set of macroRNAs (including STAiRs; STAT3-induced RNAs) that are in part specific for multiple myeloma (Hackermüller et al., 2014) . Some STAiRs seem to be tightly coupled with IL-6 signalling via STAT3 and inherent components of this pathway.
Even though knowledge on such specific interactions is beginning to evolve, for several reasons, it can be difficult to ascertain the causality of the expression of a given ncRNA: The specific effects that a ncRNA can exert on the regulation of gene expression can depend on a given context. With the exception of some classes of small ncRNAs, limited conservation at the primary sequence level complicates tracing ncRNAs between model animals. Finally, ncRNAs have been found to interfere with pathways at multiple levels. This may have pronounced consequences for the entire pathway, even though individual interactions only elicit small effects (e.g., Boll et al., 2013) . Nevertheless, increasingly, the role of lncRNAs in toxicity testing is being addressed, such as the effects of chemicals on lncRNA H19 and other imprinted genes as well as the lncRNA Hox gene transcript antisense RNA (HOTAIR; Croce, 2010; Bhan et al., 2014) . Taken together, these findings may form the basis for an AOP. Non-coding loci are also of increasing interest in environmental epidemiology. Deep methylome sequencing (i.e. an analysis of the methylation status of the genome) in a mother-child cohort study identified numerous differentially methylated regions of the DNA (DMRs) in children that were affected by their mothers' smoking habits. The majority of DMRs was associated with noncoding targets, and differential methylation was in part found to persist over years (Bauer et al., 2016) .
In conclusion, to a larger part, the differential expression of ncRNAs may be a consequence of disease or adverse effect, but many short ncRNAs do play a causal role in disease. Also for a growing number of lncRNAs, either mutation or changes in expression have been found causal for disease. Even though, to date, only few lncRNAs have been associated with pathways of toxicity, and knowledge on their role in the evolvement of apical effects is still limited, lncRNAs, and not only miRNAs, should be considered in AOP or MoA analyses.
Substance-induced alterations in ncRNA expression profiles
Nigel Gooderham, Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, UK
MiRNAs are an abundant class of genes in mammals that may control gene expression through translational repression and by inducing mRNA degradation. Since miRNAs regulate development, cell proliferation, apoptosis and differentiation, they play a central role in processes that are potentially important in toxicology. Specifically, miRNAs have been shown to interact with cellular pathways that are relevant for carcinogenesis (Calin and Croce, 2006) . Tumour-suppressor miRNAs may negatively regulate protein coding oncogenes, whereas oncogenic miRNAs may repress tumour suppressor genes. MiRNAs may also alter the epigenomics landscape by reprogramming a cell's epigenome (Moazed, 2009 ). For instance, miR-29 has been observed to inhibit the expression of DNA (cytosine-5-)-methyltransferase 3 (Fabbri et al., 2007) , and miR-101 regulates the histone methyltransferase EZH2 (enhancer of zester homolog-2) (Floris et al., 2015) . Further, combinations of miRNA may cooperate to regulate multiple proteins within cancerimportant pathways. Currently, genotoxic carcinogens can be identified reliably and quickly using a weight-of-evidence approach that takes into account structural information, in vitro assays, and in vivo DNA damage assays. By contrast, there are no regulatorily-accepted short-term tests that allow predicting non-genotoxic carcinogenicity. To investigate if changes in miRNA expression might constitute early indicators of substance-induced carcinogenicity with adequate sensitivity and specificity, and provide information on mechanisms of toxicity, a spectrum of liver carcinogens was investigated in 90-day oral toxicity studies in Fisher rats. Between 3 and 5 animals per treatment group were used. The liver carcinogens were applied at carcinogenic doses, whereas additional noncarcinogenic substances were applied at the respective maximum tolerated dose. In none of the test groups did tumours become evident by the end of the exposure period.
Total RNA was extracted from the liver and fluorescently labelled. RNA quality was determined using an Agilent Bioanalyser, and expression profiles were assessed using the Agilent miRNA microarray platform and microarray scanner. The scan data were further processed using the Agilent Feature Extraction software. For miRNA hybridisation signals (i.e. for the detection of expressed miRNA), a threshold of 1 was set, the signals were log-2 transformed, and miRNA expression was normalised to the 75th percentile using the GeneSpring GX software (all equipment and software: Agilent Technologies, USA). One-way ANOVA with Benjamini-Hochberg multiple testing correction followed by Tukey's test was used to identify dysregulated miRNAs. Targeted quantitative real-time polymerase chain reaction (qRT-PCR) was used to confirm differential miRNA expression between control and test groups.
MiRNAs that were not detected in at least 50% of the samples of any test group were excluded from the evaluation. Thereby, 21 miRNAs were identified as differentially expressed, and hierarchical clustering revealed specific patterns of miRNA expression (Koufaris et al., 2012) . These miRNAs appeared to regulate pathways that are frequently disrupted during chemical carcinogenesis or implicated in the progression or suppression of carcinogenesis, and these same miRNAs had previously been found to be dysregulated in tissuespecific tumours. Bioinformatic analysis indicated that specific pathways (such as phosphoinositide 3-kinase or epidermal growth factor) were targeted and over-represented in the analysis. This points to the need to assess the biological plausibility of the predicted miRNA-regulated pathways in respect to cancer development.
Further, a 14-day rat oral toxicity study was conducted to investigate whether the tumour promoter phenobarbital elicits miRNA-related effects in a temporal and dose-dependent manner. Again, total RNA was extracted from the liver, labelled and profiled using the Agilent microRNA microarray platform (Agilent Technologies, USA). While there were no obvious statistically significant microarray responses during the first 7 days of treatment, within 14 days, clustering could be observed and a distinct doserelated time-dependent effect on the miRNA expression profiles could be shown .
In summary, the mentioned 90-day and 14-day studies suggest that both genotoxic and epigenetic carcinogens can dysregulate miRNA expression to produce a 'fingerprint' that can be detected long before tumours develop in the treated animals. The miRNA 'fingerprint' appears to be compound-specific, and it appears to change in a dose-and time-dependent manner. Details of the miRNA 'fingerprint' can offer insight into potential MoAs. Consequently, the concept that miRNAs are biomarkers of toxicity, such as substance-induced carcinogenesis, is highly attractive. It offers the potential to identify translational biomarkers that reflect the progression of such pathological conditions Gooderham and Koufaris, 2014 In the past years, increasing insight has been gained into the physiological and pathophysiological roles of many important classes of ncRNAs. This also included the discovery of new gene silencing mechanisms, such as RNA interference (RNAi) or miRNAmediated inhibition of specific protein synthesis. These discoveries have substantially enhanced the understanding of intra-and extracellular communication beyond proteins, and they provide important information on the basis of various diseases involving aberrant ncRNA expression. Importantly, they also allow for the exploration of these mechanisms for therapeutic purposes. Major players of RNA-based therapies include antisense oligonucleotides and siRNAs, locked nucleic acid anti-miRs, tiny locked nucleic acid anti-miRs, miRNA sponges and antagomiRs (i.e. chemically modified oligonucleotides that target specific miRNAs), miRNA mimics and ribozymes.
As a rule, RNA-based therapeutic agents are too large as molecules, negatively charged and not sufficiently stable in biological fluids. This constitutes technical disadvantages over many other pharmaceuticals mainly with regard to poor pharmacokinetics. Therefore, chemical modifications and/or formulations have to be implemented to allow for therapeutic use, and despite many years of research, the issue of delivery still remains a major obstacle in therapeutic RNA use. While problems persist, RNA-based therapeutics allow for broader target selection and offer new therapeutic strategies particularly as they do not in general elicit antibody responses, even when they are bound to proteins (Ling et al., 2013) . NcRNA-based therapies either aim at restoring normal ncRNA functionalities or at using small RNA molecules to trigger desired therapeutic effects. For example, RNAi allows for the inhibition of any target gene of choice. This provides the opportunity to develop novel concepts in therapy also with regard to otherwise 'undruggable' genes.
Consequently, since its discovery in the late 1990s, RNAi-based therapeutics have been used in more than 50 clinical trials involving 26 different siRNAs (Ling et al., 2013; Lundin et al., 2015; Wittrup et al., 2015) . Two phase III clinical trials are in progress to treat familial neurodegenerative and cardiac syndromes caused by transthyretin mutations (Singh and Peer, 2016) while studies on the potential of miRNA replacements or miRNA inhibitions to reduce hypertrophic dermal scarring by targeting connective tissue growth factor or to treat pancreatic cancer have also started (Singh and Peer, 2016) . Outstanding issues in ncRNA therapy, however, are targeted RNA-drug delivery to specific organs, specificity, efficacy and absence of side effects (Wittrup et al., 2015) . Various RNAdelivery strategies, including the use of nanocarriers, and chemical RNA modifications have been developed and are currently under pre-clinical and clinical investigation (Dai and Tan, 2015; Grünweller and Hartmann, 2016; Singh and Peer, 2016) .
Technical issues related to the use of ncRNAs as biomarkers for regulatory toxicology
Frank Slack, Department of Pathology, Director, Institute for RNA Medicine, Beth Israel Deaconess Medical Center -BIDMC Cancer Center Harvard Medical School, USA MiRNAs have been found in all multicellular eukaryotes investigated so far, and they can regulate the expression of important disease genes, e.g. oncogenes and tumour suppressors (Chen et al., 2008; Chin and Slack, 2008; Lawrie et al., 2008; Mitchell et al., 2008) . Accordingly, miRNAs can be useful diagnostic and prognostic markers for diseases, and they are emerging as therapeutic targets and targeted therapeutics in different diseases, including cancer (Lu et al., 2005; Calin and Croce, 2006; Kasinski and Slack, 2011) . For instance, RNA expression profiling points to miR-34a as important and prognostic biomarker in triple-negative breast cancer (Kato et al., 2009; Adams et al., 2016) .
A suitable starting point in investigating the applicability of miRNAs as therapeutic targets or agents is to measure their relative or absolute levels in normal and diseased tissues. MiRNA profiles can be obtained from (fresh, fixed or frozen) tissues, organs, cells and subcellular fractions as well as from all relevant body fluids. MiRNAs are stable in the blood and other body fluids (Weber et al., 2010; Mitchell et al., 2008) .
Technologies for detecting miRNAs include Northern blotting, in situ hybridisation, (low density) qRT-PCR, microarray technologies, and miRNA sequencing (RNA-Seq) (Johnson et al., 2007; Chiang, 2014) . Each technology has its own strengths and limitations. While Northern blotting has very low throughput and sensitivity, it can often detect both mature and precursor forms of miRNA. In situ hybridisation also has low throughput and low sensitivity, but it provides the opportunity to detect the localization of miRNAs in tissues and subcellular regions. Microarray technologies are relatively cheap, but they have lower specificity and dynamic ranges than other technologies since the microarray platforms can only detect the specific RNAs for which they were designed. QRT-PCR has high sensitivity and specificity, and low and medium throughput options are commercially available. While RNA-Seq is relatively expensive, it has an extremely high throughput, it is highly sensitive, and it provides the option of detecting novel miRNAs and other RNA species (Baker, 2010) .
Even though miRNAs rankings are concordant between different technologies, their outcomes cannot be compared in a quantitative manner (Baker, 2010) . One of the drawbacks of RNASeq is that many miRNAs have isomeric forms that can be detected using RNA-Seq, but possibly not with other detection systems. As a result, it is difficult to directly compare the data obtained using different technologies. Further challenges to the detection and diagnostic use of miRNAs include the small sizes of the molecules, delivery and specificity issues, the determination of 'normal' miRNA levels, and the fact that very many miRNAs are only expressed at very low levels (Cheng et al., 2015) . Even though the available technologies allow detecting such low levels of miRNAs, their biological implications remain to be determined.
Generally, whereas miRNA expression profiling provides first information on biomarkers of interest, miRNA levels alone do not allow determining their functionalities (Pritchard et al., 2012) . As a rule, such determinations require mouse knock-out or knock-in models or 'therapeutic' interventions, using, e.g., anti-miRs that inhibit miRNA function and/or expression, miRNA mimics that increase miRNA expression, viral pre-miR and miRNA sponges or miRNA luciferase sensors.
Risk assessment considerations for ncRNAs in agricultural products and applications
Jan Verhaert and Jay S. Petrick, Monsanto Company, Belgium and USA, respectively
The RNA interference (RNAi) pathway has been recognized in crops for over a decade. Recent advances in technology have lead to advances in agricultural applications based on the RNAi pathway. RNA-based traits are the basis for phenotypes in conventional crops, with soybean seed coat colour and maize stalk colour serving as examples of RNA-based gene regulation harnessed through selective breeding (Tuteja et al., 2004; Della Vedova et al., 2005; Koseki et al., 2005) . In addition, RNA-based technologies have been successfully employed to introduce new traits in crops, such as virus resistance, altered oil composition in soybeans, and insect protection against corn rootworm. These types of traits have been risk assessed and approved by multiple regulators across the globe. RNA has an extensive history of safe consumption, and humans and animals routinely consume small RNAs and longer double-stranded RNAs in staple foods that have 100% sequence identity to the consuming human or animal without impact to health (Ivashuta et al., 2009; Jensen et al., 2013; Frizzi et al., 2014) . This safe consumption results in part from extensive barriers to ingested RNAs, such as low gut pH, nucleases, multiple membrane barriers, and rapid renal elimination of RNA . These barriers are also evidenced by drug delivery challenges faced by developers of oligonucleotide-based drugs (Juliano et al., 2009; O'Neill et al., 2011; Petrick et al., 2013) . Further studies in mammals indicate that ingested double-stranded RNAs, even those targeting a gene in the test species, do not produce adverse health effects in these animals (Petrick et al., 2015) . Whereas RNA-based technologies provide new tools to address agricultural challenges, the overall weight-of-evidence including historical knowledge as well as new empirical evidence shows that these technologies are safe and their safety assessment can be addressed using the current safety assessment framework.
Panel discussion: enhancing the applicability of ncRNAs as biomarkers for risk assessment
The moderator of the panel discussion, Saskia van der Vies, VU University Medical Centre, NL, invited all panellists (see below) to make a statement addressing the following questions: How is the abundance of ncRNAs currently managed? Which knowledge gaps and knowledge needs prevail that stand in the way to applying ncRNAs as biomarkers for regulatory toxicology and RA? Which ncRNA-related data are relevant for RA? What is key to data analysis and data evaluation? The statements from the panellists were followed by an open floor discussion.
Statements from the panel
Frank Slack, Harvard University, USA: It is equally evident that ncRNAs have great potential to be used as biomarkers and that extensive knowledge gaps must be addressed before this goal can be met. Current investigations focus on analysing data to determine the best suitable ncRNAs and to elucidate how they fit into specific pathways. Generally, knowledge on ncRNAs is just beginning to evolve, and new classes of RNAs, such as circular RNAs, have only been discovered in the last years. Therefore, also an understanding on their tissue-specific presence or functionalities is still at its very beginning. It is very likely that further classes of RNAs remain to be discovered, just as miRNAs might not be the smallest RNAs present in organisms.
Reza J. Rasoulpour, Dow AgroSciences, USA: The available knowledge on ncRNAs can indirectly or directly benefit substance RA, i.e. when new molecules are concertedly designed, on the one hand, and when specific ncRNA signatures are identified in test animals, on the other hand. In combining exposure and hazard assessment during RA, ncRNA expression profiling can provide biological explanations on the mechanisms of toxicity that specific substances can affect. Eventually, such ncRNA expression profiling might provide opportunities to improve regulatory toxicity testing.
Kerstin Schmidt, BioMath GmbH, Germany: The time-and dosedependent up-and down-regulation in response to toxic substances qualifies ncRNAs as useful biomarkers for toxicological studies. NcRNA expression profiles might supplement or even substitute conventional parameters that are obtained by, e.g., haematology or clinical biochemistry. NcRNAs, as new parameters, could be integrated into consolidated test vs. control group comparisons. Basically, the familiar principles to statistically analyse potential apical effects and dose-response relationships are also adoptable to ncRNA expression profiling. In fact, such approaches are very similar to current toxicological testing: Even though only single parameters are measured in the current toxicity tests, these parameters are jointly evaluated to address complex toxicological endpoints. Challenges of quantification and data interpretation are not limited to the harmonization of techniques to measure ncRNAs. Standardized procedures are also needed for data normalization and referencing. Further, standard statistical estimators must be established to ensure comparability and to facilitate assessment, also of the biological relevance of effects. Historical control data and effect sizes of potential toxicological interest (e.g. with respect to the up-or down-regulation of genes) have to be established. It has to be clarified whether the test group sizes indicated in current test guidelines provide sufficient statistical power to detect ncRNA effect sizes. Finally, modern statistical methodologies and presentation methods should be implemented to enhance comprehensive analyses and interpretation of results (Schmidt et al., 2016) .
Tim Gant, PHE, UK: Research on ncRNAs is a technology-driven process that yields an abundance of data. In making use of ncRNA expression profiles for RA, interpretation of the collected data is the biggest challenge, as is also known for 'omics technologies. Some of the information that these technologies provide is not necessarily fully understood. Nevertheless, it is beneficial to gather all data, even though it can be challenging to manage large datasets. Knowledge gaps with respect to evaluating data by applied bioinformatics prevail. It is not yet understood which specific data are relevant for toxicological RA, which changes in ncRNA expression are causal and which are consequential, or how ncRNAs are involved in toxicological mechanisms. Such an understanding, however, is a prerequisite to selecting ncRNAs as biomarkers for RA. Presumably, different types of substances and different patterns of change are related to specific mechanisms of toxicity.
Open floor discussion
Generally, cells can counterbalance external insults with sufficient efficiency until a certain level or duration of exposure. Alterations in ncRNA expression profiles can indicate a cell's attempt to regain homeostasis, and, therefore, they can be recorded before the cell is irreversibly damaged. As such, changes in ncRNA expression can constitute molecular initiating events. However, depending on the given context, they might also constitute downstream steps of an AOP. In both cases, relevant ncRNAs can be early predictors of specific toxicological pathways. Hence, they can become useful biomarkers for regulatory toxicology. To understand mechanisms of toxicity, the point at which the system is irreversibly disrupted should be identified. Further, to build a mechanistic understanding on ncRNA-induced effects, it is essential to establish dose-response relationships of alterations in ncRNA expression profiles. Another key issue is to determine if changes are sensitive. Very often, changes are small (e.g. five-fold increases of singular molecules), in which case they are difficult to detect.
Extensive discussions addressed the question whether ncRNA expression changes were 'cause or consequence' of adverse effects and what implications this might have in making use of ncRNA technologies in regulatory toxicology. While ncRNA expression changes might not be directly causative, the subsequent downstream effects might nevertheless induce toxicity. Such ncRNA expression changes can be thought of as causal. By comparison, ncRNA expression changes that occur in response to a particular exposure and/or toxicity, but that are not involved in the induction of adverse downstream effects, can be thought of as consequential. Such changes may also be useful as biomarkers of substance exposure in regulatory toxicology. Even if it is not fully understood whether alterations in the expression of a given ncRNA are 'cause or consequence' of a specific apical effect, this ncRNA may nevertheless be a potentially useful biomarker for regulatory toxicology and RA.
From a toxicological point of view, concerns regarding the applicability of ncRNA expression profiling are similar to the ones that have been voiced with respect to gene expression (transcriptome) profiling. Data can indicate that, e.g., specific carcinogenic genes are enhanced or expressed. Upon too simplistic evaluation, this can be interpreted as giving rise to concern, even in the absence of a downstream apical effect. It is essential to understand the phenotypic consequences of a given ncRNA change, i.e. to perform a functional verification and validation of the ncRNA expression profile. At best, the physiological and pathological roles of all ncRNAs that rank high in expression profiles should be known. To date, such functionalities are investigated rather randomly by changing the expression of a specific ncRNA, e.g. by using knockout animals (or genetically modified cell lines) that lack a specific gene or ncRNA and searching for phenotypic (or cellular) alterations.
A way forward in identifying ncRNA fingerprints that might be applicable to determine, e.g. a substance's carcinogenic potential, might be to expose different animal species to a set of substances with known carcinogenicity and to comparatively assess the resulting ncRNA expression profiles. Generally, the most relevant animal species and animal model for a given human issue should be identified, just as the human health relevance of findings should be ensured. Research should also aim at investigating the biological implications of (different levels of) ncRNAs present in body fluids. Even though ncRNAs (just as other biomarkers in the blood) can be exceptionally stable when bound to proteins, they can nevertheless be removed from the blood very quickly, i.e. before sampling can be performed. To date, it is largely unclear from which organs or tissues the ncRNAs present in body fluids come from, or if they are truly specific to the process under investigation.
Importantly, research reports should not only include all data that were collected, but they should also clearly describe how the data were collected and analysed. Further investigations should aim at identifying the technology that is best suited to determine biologically relevant ncRNA alterations (that are not merely technological artefacts or sample contaminations).
Breakout sessions: the identification of research priorities
There was considerable overlap between the topics addressed in the breakout groups with resulting concordant or complementary recommendations. Therefore, the outcomes of the three breakout groups from the breakout sessions 1 and 2, respectively, are presented jointly, rounded up by comments provided during the subsequent plenary discussions. Generally, there are three important drivers of research on ncRNAs as biomarkers for regulatory toxicology. First, the 3Rs principle to reduce the number of studies and the number of animals used in the studies (Russell and Burch, 1959 ) that has been implemented in Directive 2010/63/EU on the protection of animals used for scientific purposes. Second, the motivation to streamline and accelerate substance development and the RA process. (Research on ncRNAs might also serve to use the respective technologies to modify, e.g., plants and therapeutic agents.) Third, the incentive to gain knowledge that is of increased biological and toxicological relevance.
Accordingly, research on ncRNAs as biomarkers for regulatory toxicology should not only strive to replace apical endpoints by earlier molecular or cellular effects, but it should aim to create a new toxicological paradigm that provides more comprehensive information. In certain areas of toxicology, the current standard tests have scientific shortages. Knowledge gaps include, but are not restricted to ways to assess non-genotoxic carcinogenicity and reproductive/transgenerational toxicity, including in utero exposure leading to adult diseases, the effects of long-term low-dose exposure and problems in the toxicological evaluation of mixtures. Research to enhance the utility of ncRNAs as biomarkers for regulatory toxicology should also address such scientific shortages of standard toxicity tests and the way that specific ncRNAs might contribute to overcoming them. Even though the goal to gain knowledge that is of increased biological and toxicological relevance might only be reached in the long term, it is of high scientific relevance since an improved biological understanding of mechanisms of toxicity will serve to improve the RA of substances and products.
Current research is most advanced for miRNAs. Nevertheless, for the time being, ncRNA-related research aiming at identifying biomarkers for regulatory toxicology should not be restricted to promising miRNAs, but it should also be open to possibly emerging evidence on the suitability of other classes of ncRNAs, such as lncRNAs.
All research questions should be pursued in literature reviews and in experimental projects. To gain new data, it might be beneficial to include ncRNA expression profiling, just as 'omics and epigenetics technologies, in the control groups of Good Laboratory Practice-compliant rat 90-day oral toxicity studies that include properly defined kinetics and (histo-)pathological evaluations. Thereby, ncRNA assessments will be performed in parallel with other readouts, and historical control group databases will be set up. All research should preferably be conducted in the form of collaborative studies, pooling data from different companies and institutions. All of these premises will allow collecting ncRNA data within a regulatory context, and they will enhance a prospective comparative assessment of the new tools.
To determine the role that ncRNAs might play in regulatory toxicology, a profile of the 'normal' situation and its variations in maintaining cellular homeostasis remain to be elucidated. The historical control databases will provide an overview of the ranges of normal ncRNA expression levels. Further, the dose-response relationships of substance-induced deviations from normality and the phenotypic consequences of different ncRNA expression levels should be determined. These actions will serve to identify key ncRNAs that are relevant for cell homeostasis or pathogenesis, as applicable.
Beyond an assessment of differences in ncRNA expression profiles that will be relevant for toxicological assessments (physiological variations vs. pathological changes), optimal testing systems have to be defined with regard to pathological readout and kinetics over time. An understanding on mechanisms of toxicity involving ncRNAs will form a basis to determine species-specific and tissuespecific differences in susceptibility to substance-induced effects. It will be of great value for RA to identify ncRNAs that are related to the development of specific apical effects and to be able to trace them in vitro and in vivo and across animal species and strains.
Research addressing the possible relevance of changes in the expression of selected ncRNAs for toxicological assessments should strive to distinguish between physiological variations and pathophysiological alterations. To date, it is unclear which order of magnitude is relevant for a given ncRNA, i.e. which changes can lead to downstream effects on established target genes. Further, specific MoAs have not yet been discerned. Ideally, all knowledge gained on pathophysiological alterations of ncRNA expression should be integrated into AOPs, e.g. by identifying the specific consequences of ncRNA alterations on different levels, including protein levels, enzyme compositions, and deviations from the phenotype.
Relevant body compartments for ncRNA analysis need to be defined. This includes non-invasive (blood, urine, and other body fluids) and invasive assessments (classical additional target organs depending on prior non-invasive analysis to identify representative miRNAs for specific organs or for specific early events, e.g. with respect to tumour development). As the example of miRNAs that are involved in acetaminophen hepatotoxicity reveals, substanceinduced miRNA changes can be investigated in a time-dependent manner already shortly after exposure to the substance when conventional parameters are not yet affected (Ward et al., 2012) . In fact, this constitutes one of the advantages of ncRNA expression profiling over conventional techniques. Also with respect to substance-induced carcinogenicity, different ncRNA expression profiles are to be expected during pre-tumour and post-tumour investigations. Hence, changes in ncRNA expression should always be investigated in a time-dependent manner, and they should always be related to normal expression levels.
All research efforts should be application-oriented. The standardization and validation of ncRNA expression profiling technologies should be advanced, and guidelines on the reporting of data and results from ncRNA studies should be set up. NcRNA-related tools will most likely not be beneficial in isolation, but they will add to a weight-of-evidence during RA. Accordingly, ncRNA expression profiling should be considered together with other modern technologies, such as 'omics and epigenetics.
Finally, ncRNA-related research should not be restricted to carcinogenicity-related topics, but it should cover a wide range of toxicological endpoints. The pathological consequences and respective changes in ncRNA expression of long-term low-dose substance applications should also be addressed. Comprehensive literature surveys should be conducted to review the state-of-the-art role that ncRNAs play in the evolvement of apical effects. Such surveys should aim to identify key ncRNAs that might be predictive biomarkers for specific toxicological endpoints. At least initially, well-established ncRNAs should be addressed with priority, which will most likely mainly include miRNAs (e.g. miR-155 and miR-122). Nevertheless, the survey should also take into account other classes of ncRNA (e.g., the lncRNA HOTAIR). Additionally, promising candidates may be obtained by bioinformatic re-analysis of existing data sets. The suitability of candidate ncRNA should be defined with regard to organ and tissue specificity and pathological functionality (e.g. tumour promoting properties). The review should cover all available relevant information on ncRNAs. In this regard, 'relevant' studies should cover both ncRNA expression analysis and phenotype assessments.
As an outcome of the literature survey, a list of candidate ncRNAs to choose from for the subsequent experimental project should be drawn up. This list may also include new, hitherto untested ncRNAs.
Experimental project
To substantiate the relevance of selected ncRNAs as biomarkers for toxicity studies, retrospective analyses of ncRNA expression profiles (e.g. from surplus samples from control groups from existing regulatory studies) may be supplemented by performing new 90-day rat oral toxicity tests. The experimental project should be designed to allow the determination of dose-response relationships, and it should include ncRNA profiling of blood samples. The choice of rat strain should be justified, just as the selection of 2e3 target organs (e.g. liver, thyroid, and kidney). All studies should be run in parallel in multiple laboratories, and blinded samples should be used for ncRNA analysis.
The experimental project should aim at establishing normal (i.e. physiological) ncRNA expression profiles that include the biological variability of healthy individuals (i.e. the control groups). Covering the range of intra-and inter-individual variability in ncRNA expression levels, the biological variability is most likely affected by a multitude of parameters, including polymorphic differences and the diet.
The normal ncRNA expression profiles should be used to assist in the interpretation of substance-induced changes in ncRNA expression profiles. It should be strived to link profiles to pathological findings (phenotypic alterations). This should also serve to improve an understanding of MoAs. Therefore, the experimental project may be specifically designed to address areas of toxicology where current methods to understand MoAs are poor, (e.g. nongenotoxic carcinogenesis, immunotoxicity, reproductive/intergenerational toxicity, or low-dose and long-term toxicity).
The experimental project may also be conducted in the form of case studies investigating, e.g., changes in the expression of specific ncRNAs taking into account dose-response relationships and temporal aspects. Such case studies should address whether the polymorphism of ncRNAs is likely to have functional consequences and whether specific epigenetic events govern other epigenetic events.
Generally, the project should consider the results from relevant disease-related genomics projects, and data-sharing between different companies and public health departments should be encouraged. As an outcome of this project, new predictive biomarkers of toxicity and disease states should be identified. For instance, it might be shown that a hepatotoxic substance does not change the ncRNA profile in other organ systems.
Subsequent follow-up research should include a verification and validation of the ncRNA expression profiling, e.g., by using unspecific chemicals and/or by including further organ systems in the follow-up studies. Additionally, data fusion approaches should be used to comparatively analyse ncRNA expression profiles, data from 'omics and epigenetics technologies, and findings gained using classical toxicological parameters (including (histo-) pathological evaluation). This will provide added value from existing information and advance a meaningful and comprehensive interpretation of data obtained in ncRNA expression profiling, 'omics and epigenetics technologies. Even though the precise relationships between these data (or technologies) are not yet understood, they all merge into specific AOPs.
Consensus should be developed on how to conduct ncRNA expression profiling in a toxicological and regulatory context, including best practice of reporting the outcome of such studies. This part of the experimental work should also encompass initiatives to improve the standardization of the respective technologies to form a basis for their verification and validation and to set up guidelines for reporting the outcome of ncRNA studies.
Close of the workshop
Wrapping up the workshop, Helmut Greim, Technical University Munich, Germany, highlighted that, in the long-term, knowledge of ncRNAs can serve to understand specific mechanisms of toxicity, e.g., with respect to genotoxic and non-genotoxic carcinogenicity, reproductive/transgenerational toxicity, mixture toxicology, and long-term low-dose effects. All ncRNA methodologies should be standardised and validated, and guidance for the reporting of data should be established. NcRNA analysis tools can be incorporated into standardised in vitro assays and in vivo repeated-dose studies used for RA, applying a holistic approach that incorporates epigenetic mechanisms, 'omics technologies (and gene methylation and acetylation) and that serve to establish correlations between changes in ncRNA expression and the corresponding changes in cellular function.
Taken together, the research priority areas identified during the workshop will serve to recognize key ncRNAs that are relevant for cell homeostasis and/or pathogenesis and to advance a mechanistic understanding of toxicological pathways. The outcomes of the projects should be used to integrate knowledge on ncRNAs into AOPs, e.g. to identify the consequences of changes in the expression of a given ncRNA on the subsequent steps of a relevant AOP, including protein levels, enzyme compositions, and deviations from the phenotype.
Importantly, all those involved in regulatory toxicology and the RA of substances should be continuously informed on the potential applicability of ncRNA data for RA. In the long term, ncRNA expression profiling has the potential to improve RA by enhancing hazard predictions at earlier stages, and it may serve the goals to reduce animal testing and to reduce the costs and time required to market innovative products.
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